Krasa/Krasa
multiple strains
|
increased lung adenoma incidence |
J:17778,
J:17850
|
Krasb/Krasb
multiple strains
|
decreased lung tumor incidence |
J:17778,
J:17850
|
Krastm1.1Khai/Kras+
Tg(Mx1-cre)1Cgn/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6J * CBA/J
|
abnormal hematopoietic system morphology/development |
J:276349
|
|
anemia |
J:276349
|
|
decreased hemoglobin content |
J:276349
|
|
enlarged spleen |
J:276349
|
|
increased leukocyte cell number |
J:276349
|
|
increased myeloid cell number |
J:276349
|
|
increased myeloid cell number in bone marrow |
J:276349
|
|
premature death |
J:276349
|
Krastm1.1Khai/Kras+
Tg(Fabp1-cre)1Jig/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N
|
abnormal colon morphology |
J:276349
|
|
abnormal large intestine crypts of Lieberkuhn morphology |
J:276349
|
Krastm1.1Khai/Kras+
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N
|
normal
neoplasm |
J:276349
|
Krastm1Bbd/Kras+
involves: 129S1/Sv * 129X1/SvJ
|
decreased survivor rate |
J:172200
|
|
increased lung non-small cell carcinoma incidence |
J:172200
|
|
premature death |
J:172200
|
Krastm1Bbd/Kras+
Tg(CMV-cre)1Cgn/?
involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6
|
abnormal cell proliferation |
J:86101
|
|
increased lung adenocarcinoma incidence |
J:86101
|
|
increased lung adenoma incidence |
J:86101
|
|
increased papilloma incidence |
J:86101
|
|
increased sarcoma incidence |
J:86101
|
|
premature death |
J:86101
|
|
prenatal lethality, incomplete penetrance |
J:86101
|
|
respiratory distress |
J:86101
|
Krastm1Bbd/Kras+
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:143034
|
|
increased prostate intraepithelial neoplasia incidence |
J:143034
|
|
prostate gland hyperplasia |
J:143034
|
Krastm1Bbd/Kras+
Tg(CMV-cre/ERT)1Ipc/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
abnormal fibroblast proliferation |
J:86101
|
|
Harderian gland hyperplasia |
J:86101
|
|
increased lung adenocarcinoma incidence |
J:86101
|
|
increased lung adenoma incidence |
J:86101
|
|
premature death |
J:86101
|
|
respiratory distress |
J:86101
|
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ
|
increased adenoma incidence |
J:161780
|
|
increased lung non-small cell carcinoma incidence |
J:161780
|
|
premature death |
J:161780
|
Krastm1Bbd/Krastm1Bbd
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
embryonic lethality during organogenesis, complete penetrance |
J:86101
|
Krastm1Bbd/Krastm1Bbd
Tg(Cela1-tTA)#Eps/?
Tg(tetO-cre)3Jig/?
involves: 129S1/Sv * 129X1/SvJ * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:119988
|
|
increased tumor latency |
J:119988
|
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ
|
increased cell proliferation |
J:161780
|
|
increased lung non-small cell carcinoma incidence |
J:161780
|
|
increased lung tumor incidence |
J:161780
|
|
premature death |
J:161780
|
Krastm1Epa/Krastm1Epa
129P2/OlaHsd-Krastm1Epa
|
no abnormal phenotype detected |
J:86863
|
Krastm1Epa/Krastm1Epa
involves: 129P2/OlaHsd * C57BL/6
|
no abnormal phenotype detected |
J:86863
|
Krastm1Mok/Kras+
involves: 129S/SvEv * C57BL/6J
|
no abnormal phenotype detected |
J:42943
|
Krastm1Mok/Krastm1Mok
involves: 129S/SvEv * C57BL/6J
|
abnormal fetal cardiomyocyte proliferation |
J:42943
|
|
abnormal heart morphology |
J:42943
|
|
decreased embryo size |
J:42943
|
|
embryonic growth retardation |
J:42943
|
|
normal
hematopoietic system phenotype |
J:42943
|
|
increased neuron apoptosis |
J:42943
|
|
normal
liver/biliary system phenotype |
J:42943
|
|
prenatal lethality, complete penetrance |
J:42943
|
|
small heart |
J:42943
|
|
thin myocardium |
J:42943
|
|
thin ventricular wall |
J:42943
|
Krastm1Tyj/Krastm1Tyj
involves: 129S2/SvPas
|
abnormal definitive hematopoiesis |
J:43433
|
|
anemia |
J:43433
|
|
decreased embryo size |
J:43433
|
|
fetal growth retardation |
J:43433
|
|
increased apoptosis |
J:43433
|
|
liver hypoplasia |
J:43433
|
|
pale liver |
J:43433
|
|
pallor |
J:43433
|
|
pericardial edema |
J:43433
|
|
prenatal lethality, complete penetrance |
J:43433
|
|
small liver |
J:43433
|
Krastm2Tyj/Kras+
involves: 129S2/SvPas
|
abnormal bronchus morphology |
J:136369
|
|
increased carcinoma incidence |
J:129627
|
|
increased fibrosarcoma incidence |
J:129627
|
|
increased hemangiosarcoma incidence |
J:129627
|
|
increased lung adenocarcinoma incidence |
J:136369
|
|
increased lymphoma incidence |
J:129627
|
|
increased mesothelioma incidence |
J:129627
|
|
increased papilloma incidence |
J:129627
|
|
increased sarcoma incidence |
J:129627
|
|
increased skin papilloma incidence |
J:68981
|
|
increased squamous cell carcinoma incidence |
J:129627
|
|
increased T cell derived lymphoma incidence |
J:68981
|
|
increased tumor incidence |
J:129627
|
|
premature death |
J:68981,
J:129627
|
Krastm2Tyj/Kras+
involves: 129S2/SvPas * C57BL/6
|
abnormal large intestine crypts of Lieberkuhn morphology |
J:68981
|
|
increased lung adenocarcinoma incidence |
J:68981
|
|
increased lung adenoma incidence |
J:68981
|
|
increased lung tumor incidence |
J:68981
|
|
increased skin papilloma incidence |
J:68981
|
|
increased T cell derived lymphoma incidence |
J:68981
|
|
increased tumor incidence |
J:68981
|
|
premature death |
J:68981
|
Krastm3Bbd/Krastm3Bbd
B6.129-Krastm3Bbd
|
embryonic lethality, complete penetrance |
J:101977
|
Krastm3Tyj/Kras+
involves: 129S4/SvJae
|
increased lung tumor incidence |
J:119477
|
|
increased skin papilloma incidence |
J:68981
|
|
increased T cell derived lymphoma incidence |
J:68981
|
|
premature death |
J:68981
|
Krastm3Tyj/Kras+
involves: 129S4/SvJae * C57BL/6
|
abnormal large intestine crypts of Lieberkuhn morphology |
J:68981
|
|
increased lung adenocarcinoma incidence |
J:68981
|
|
increased lung adenoma incidence |
J:68981
|
|
increased lung tumor incidence |
J:68981
|
|
increased skin papilloma incidence |
J:68981
|
|
increased T cell derived lymphoma incidence |
J:68981
|
|
increased tumor incidence |
J:68981
|
|
premature death |
J:68981
|
Krastm3Tyj/Krastm3Tyj
involves: 129S4/SvJae
|
increased lung tumor incidence |
J:237900
|
|
increased skin papilloma incidence |
J:237900
|
|
increased T cell derived lymphoma incidence |
J:237900
|
|
premature death |
J:237900
|
Krastm4.1Bbd/Kras+
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6J * FVB/N
|
enlarged spleen |
J:223433
|
|
premature death |
J:223433
|
Krastm4.1Bbd/Krastm4.1Bbd
129S2.129(Cg)-Krastm4.1Bbd
|
perinatal lethality, incomplete penetrance |
J:223433
|
Krastm4.1Bbd/Krastm4.1Bbd
B6J.129(FVB)-Krastm4.1Bbd
|
perinatal lethality, complete penetrance |
J:223433
|
Krastm4.1Bbd/Krastm4.1Bbd
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6J * FVB/N
|
abnormal bone marrow cell physiology |
J:223433
|
|
abnormal common lymphocyte progenitor cell morphology |
J:223433
|
|
abnormal common myeloid progenitor cell morphology |
J:223433
|
|
abnormal cranium morphology |
J:223433
|
|
abnormal ear position |
J:223433
|
|
abnormal facial morphology |
J:223433
|
|
abnormal heart morphology |
J:223433
|
|
abnormal hematopoietic system morphology/development |
J:223433
|
|
abnormal kidney morphology |
J:223433
|
|
abnormal myocardial fiber physiology |
J:223433
|
|
anemia |
J:223433
|
|
cellular necrosis |
J:223433
|
|
decreased body length |
J:223433
|
|
decreased body size |
J:223433
|
|
decreased CD8-positive, alpha-beta T cell number |
J:223433
|
|
decreased cranium length |
J:223433
|
|
enlarged spleen |
J:223433
|
|
extramedullary hematopoiesis |
J:223433
|
|
flattened snout |
J:223433
|
|
heart hyperplasia |
J:223433
|
|
increased basophil cell number |
J:223433
|
|
increased cardiac muscle contractility |
J:223433
|
|
increased cardiac output |
J:223433
|
|
increased cell proliferation |
J:223433
|
|
increased cranium height |
J:223433
|
|
increased cranium width |
J:223433
|
|
increased eosinophil cell number |
J:223433
|
|
increased granulocyte monocyte progenitor cell number |
J:223433
|
|
increased hematopoietic stem cell number |
J:223433
|
|
increased leukocyte cell number |
J:223433
|
|
increased myeloid cell number |
J:223433
|
|
increased myocardial fiber number |
J:223433
|
|
increased neutrophil cell number |
J:223433
|
|
ocular hypertelorism |
J:223433
|
|
perinatal lethality, incomplete penetrance |
J:223433
|
|
premature death |
J:223433
|
|
slow postnatal weight gain |
J:223433
|
|
spleen vascular congestion |
J:223433
|
|
thick aortic valve |
J:223433
|
|
thrombocytopenia |
J:223433
|
|
triangular face |
J:223433
|
Krastm4.1Tyj/Kras+
Not Specified
|
abnormal brain development |
J:89333
|
|
abnormal embryonic neuroepithelium morphology |
J:89333
|
|
decreased embryo size |
J:89333
|
|
embryonic lethality during organogenesis, complete penetrance |
J:89333
|
|
enlarged heart |
J:89333
|
|
increased embryonic neuroepithelium apoptosis |
J:89333
|
|
pallor |
J:89333
|
Krastm4Tyj/Kras+
B6.129S4-Krastm4Tyj
|
increased lung adenocarcinoma incidence |
J:177379
|
|
increased lung adenoma incidence |
J:177379
|
|
premature death |
J:177379
|
Krastm4Tyj/Kras+
either: (involves: 129S4/SvJae) or (involves: 129S4/SvJae * C3H/HeJ)
|
abnormal ovary morphology |
J:96296
|
|
abnormal peritoneum morphology |
J:96296
|
Krastm4Tyj/Kras+
involves: 129S4/SvJae
|
increased lung adenocarcinoma incidence |
J:207982
|
|
increased lung adenoma incidence |
J:207982
|
|
increased lung tumor incidence |
J:119477,
J:216266,
J:299900
|
Krastm4Tyj/Kras+
involves: 129S4/SvJae
|
abnormal bronchiole morphology |
J:147590
|
|
abnormal tumor morphology |
J:147590
|
|
bronchiolar epithelial hyperplasia |
J:147590
|
|
decreased tumor growth/size |
J:147590
|
|
increased lung adenocarcinoma incidence |
J:147590
|
|
increased lung adenoma incidence |
J:158937
|
|
increased lung carcinoma incidence |
J:158937
|
|
increased lung tumor incidence |
J:147590,
J:158937
|
|
increased regulatory T cell number |
J:154046
|
|
lung epithelium hyperplasia |
J:158937
|
|
premature death |
J:147590
|
|
thick pulmonary interalveolar septum |
J:147590
|
|
uterus adenomyosis |
J:154046
|
Krastm4Tyj/Kras+
involves: 129S4/SvJae * C57BL/6
|
increased lung adenoma incidence |
J:203686
|
Krastm4Tyj/Kras+
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
increased lung adenocarcinoma incidence |
J:124682
|
|
premature death |
J:124682
|
Krastm4Tyj/Kras+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae
|
increased lung tumor incidence |
J:158937
|
|
increased lung weight |
J:158937
|
|
postnatal lethality, complete penetrance |
J:158937
|
Krastm4Tyj/Kras+
Tg(Tek-cre)12Flv/0
involves: 129S4/SvJae * C3H * C57BL/6
|
normal
embryo phenotype |
J:119477
|
Krastm4Tyj/Kras+
Tg(Mx1-cre)1Cgn/0
involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA
|
abnormal definitive hematopoiesis |
J:88163
|
|
abnormal erythrocyte morphology |
J:88163
|
|
abnormal hepatobiliary system morphology |
J:88163
|
|
abnormal myelopoiesis |
J:88163
|
|
anemia |
J:88163
|
|
cachexia |
J:88163
|
|
decreased hematocrit |
J:88163
|
|
enlarged spleen |
J:88163
|
|
extramedullary hematopoiesis |
J:88163
|
|
increased esophageal papilloma incidence |
J:88163
|
|
increased granulocyte number |
J:88163
|
|
increased leukocyte cell number |
J:88163
|
|
increased lung adenoma incidence |
J:88163
|
|
increased lymphoblastic lymphoma incidence |
J:88163
|
|
increased oral papilloma incidence |
J:88163
|
|
increased papilloma incidence |
J:88163
|
|
increased skin papilloma incidence |
J:88163
|
|
increased spleen red pulp amount |
J:88163
|
|
lymphoid hyperplasia |
J:88163
|
|
myeloid hyperplasia |
J:88163
|
|
premature death |
J:88163
|
|
ruffled hair |
J:88163
|
Krastm4Tyj/Kras+
Tg(Mx1-cre)1Cgn/0
involves: 129S4/SvJae * C57BL/6 * C57BL/6J * CBA/J
|
abnormal hematopoietic system morphology/development |
J:276349
|
|
anemia |
J:276349
|
|
enlarged spleen |
J:276349
|
|
increased myeloid cell number |
J:276349
|
|
increased myeloid cell number in bone marrow |
J:276349
|
|
premature death |
J:276349
|
Krastm4Tyj/Kras+
Tg(Mx1-cre)1Cgn/0
involves: 129S4/SvJae * C57BL/6 * CBA
|
abnormal erythropoiesis |
J:87429,
J:115071
|
|
abnormal myelopoiesis |
J:87429
|
|
anemia |
J:87429,
J:115071
|
|
anisopoikilocytosis |
J:115071
|
|
decreased mean corpuscular hemoglobin |
J:115071
|
|
enlarged liver |
J:87429
|
|
enlarged spleen |
J:87429,
J:115071
|
|
increased circulating erythropoietin level |
J:115071
|
|
increased leukocyte cell number |
J:87429
|
|
increased monocyte cell number |
J:87429
|
|
increased splenocyte proliferation |
J:87429
|
|
myeloid hyperplasia |
J:87429
|
|
polychromatophilia |
J:115071
|
|
premature death |
J:87429
|
|
reticulocytosis |
J:115071
|
Krastm4Tyj/Kras+
Tg(MMTV-cre)4Mam/0
involves: 129S4/SvJae * FVB
|
submandibular gland hyperplasia |
J:89333
|
Krastm4Tyj/Kras+
Meox2tm1(cre)Sor/Meox2+
involves: 129S4/SvJae * 129S4/SvJaeSor
|
abnormal atrioventricular valve morphology |
J:119477
|
|
abnormal branching involved in lung morphogenesis |
J:119477
|
|
abnormal bronchus morphology |
J:119477
|
|
abnormal cardiovascular system physiology |
J:119477
|
|
abnormal embryonic erythrocyte morphology |
J:119477
|
|
abnormal embryonic erythropoiesis |
J:119477
|
|
conotruncal ridge hyperplasia |
J:119477
|
|
dilated respiratory conducting tube |
J:119477
|
|
double outlet right ventricle |
J:119477
|
|
edema |
J:119477
|
|
normal
embryo phenotype |
J:119477
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:119477
|
|
hemorrhage |
J:119477
|
|
impaired branching involved in bronchus morphogenesis |
J:119477
|
|
impaired branching involved in terminal bronchiole morphogenesis |
J:119477
|
|
increased hepatocyte apoptosis |
J:119477
|
|
lethality throughout fetal growth and development, complete penetrance |
J:119477
|
|
liver hypoplasia |
J:119477
|
|
pallor |
J:119477
|
|
ventricular septal defect |
J:119477
|
Krastm4Tyj/Kras+
Tg(Prm-cre)58Og/0
involves: 129S4/SvJae
|
abnormal placenta labyrinth morphology |
J:119477
|
|
abnormal placental labyrinth vasculature morphology |
J:119477
|
|
absent vitelline blood vessels |
J:119477
|
|
embryonic growth arrest |
J:119477
|
|
embryonic lethality during organogenesis, complete penetrance |
J:119477
|
|
increased embryonic tissue cell apoptosis |
J:119477
|
|
pale yolk sac |
J:119477
|
Krastm4Tyj/Kras+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * DBA
|
increased cholangiocarcinoma incidence |
J:184949
|
|
increased liver tumor incidence |
J:254370
|
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
B6.Cg-Krastm4Tyj Ptf1atm1.1(cre)Cvw
|
increased metastatic potential |
J:138959
|
|
increased pancreas tumor incidence |
J:138959
|
|
increased pancreas weight |
J:138959
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:138959
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:138959
|
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ
|
abnormal pancreatic acinar cell morphology |
J:262746
|
|
enlarged pancreas |
J:87973
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:87973,
J:116130
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:262746
|
|
increased tumor incidence |
J:87973
|
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2
|
increased pancreatic intraepithelial neoplasia incidence |
J:116129
|
Krastm4Tyj/Kras+
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO-cre)1Jaw/0
involves: 129/Sv * C57BL/6
|
abnormal branching involved in lung morphogenesis |
J:119477
|
|
abnormal bronchus epithelium morphology |
J:119477
|
|
abnormal lung epithelium morphology |
J:119477
|
|
postnatal lethality, complete penetrance |
J:119477
|
Krastm4Tyj/Kras+
Tg(KRT14-cre/ERT)20Efu/0
involves: 129S4/SvJae * C57BL/6 * CD-1 * FVB/N
|
increased mouth tumor incidence |
J:210533
|
Krastm4Tyj/Kras+
Tg(Fabp1-cre)1Jig/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N
|
abnormal intestinal epithelium morphology |
J:132357
|
|
abnormal intestinal goblet cell morphology |
J:132357
|
|
abnormal large intestine crypts of Lieberkuhn morphology |
J:132357
|
Krastm4Tyj/Kras+
Tg(Fabp1-cre)1Jig/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
abnormal colon morphology |
J:276349
|
|
abnormal large intestine crypts of Lieberkuhn morphology |
J:276349
|
|
absent Paneth cells |
J:276349
|
Krastm4Tyj/Kras+
Tg(Fabp1-cre)1Jig/0
involves: 129S4/SvJae * FVB/N
|
abnormal colon morphology |
J:89333
|
Krastm4Tyj/Kras+
Tg(KRT5-cre/PGR)1Der/?
involves: 129/Sv * C57BL/6 * FVB * ICR
|
increased skin papilloma incidence |
J:124222
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA
|
ascites |
J:164210
|
|
distended abdomen |
J:164210
|
|
enlarged pancreatic islets |
J:87196
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:116130,
J:164210
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:87196,
J:164210
|
|
pancreatic acinar-to-ductal metaplasia |
J:164210
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N
|
increased metastatic potential |
J:108298
|
|
increased pancreas tumor incidence |
J:108298
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
abnormal pancreatic duct morphology |
J:214846
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:98936,
J:214846,
J:276349
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/?
involves: 129S4/SvJae * FVB/N
|
enlarged pancreas |
J:87973
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:87973
|
Krastm4Tyj/Kras+
Shhtm2(cre/ERT2)Cjt/Shh+
involves: 129S4/SvJae * 129S6/SvEvTac
|
normal
integument phenotype |
J:172048
|
Krastm4Tyj/Kras+
Tg(Krt1-15-cre/PGR*)22Cot/0
involves: 129S4/SvJae * C57BL/6 * C57BL/6J * SJL/J
|
increased papilloma incidence |
J:203922
|
Krastm4Tyj/Kras+
Tg(Krt1-15-cre/PGR*)22Cot/0
involves: 129S4/SvJae * C57BL/6J * SJL/J
|
increased facial tumor incidence |
J:172048
|
|
increased lip tumor incidence |
J:172048
|
|
increased skin papilloma incidence |
J:172048
|
|
increased skin tumor incidence |
J:172048
|
Krastm4Tyj/Kras+
Tg(Upk2-cre)6Xrw/0
involves: 129S4/SvJae * FVB/N
|
normal
neoplasm |
J:174242,
J:234236
|
|
normal
renal/urinary system phenotype |
J:234236
|
Krastm4Tyj/Kras+
Tg(Scgb1a1-cre)1Kkw/?
involves: 129 * C57BL/6 * FVB/N
|
increased inflammatory response |
J:107260
|
|
increased lung adenocarcinoma incidence |
J:107260
|
|
premature death |
J:107260
|
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129S4/SvJae * FVB
|
abnormal melanocyte morphology |
J:164588
|
|
hyperpigmentation |
J:164588
|
|
increased melanoma incidence |
J:164588
|
Krastm4Tyj/Kras+
Tg(TPO-cre)1Shk/0
129.Cg-Krastm4Tyj Tg(Tpo-cre)1Shk
|
normal
endocrine/exocrine gland phenotype |
J:147732
|
Krastm4Tyj/Kras+
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae
|
abnormal colon goblet cell morphology |
J:132357
|
|
abnormal intestinal epithelium morphology |
J:132357
|
|
abnormal large intestine crypts of Lieberkuhn morphology |
J:132357
|
Krastm4Tyj/Kras+
Tg(Pbsn-cre)20Fwan/0
involves: 129S4/SvJae * FVB/NCrl
|
abnormal intestine morphology |
J:178461
|
|
abnormal prostate gland physiology |
J:178461
|
|
increased prostate intraepithelial neoplasia incidence |
J:178461
|
|
prostate gland hyperplasia |
J:178461
|
Krastm4Tyj/Kras+
Krt19tm1(cre/ERT)Ggu/Krt19+
involves: 129S4/SvJae * 129S6/SvEvTac
|
abnormal skin sebaceous gland morphology |
J:172048
|
|
enlarged sebaceous gland |
J:172048
|
|
increased cell proliferation |
J:172048
|
|
increased hair follicle cell proliferation |
J:172048
|
|
increased lip tumor incidence |
J:172048
|
|
increased skin papilloma incidence |
J:172048
|
|
increased skin tumor incidence |
J:172048
|
|
sebaceous gland hyperplasia |
J:172048
|
Krastm4Tyj/Kras+
Scgb1a1tm1.1(cre)Fjd/Scgb1a1+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ
|
abnormal lung morphology |
J:131721
|
|
increased lung adenoma incidence |
J:131721
|
|
increased lung tumor incidence |
J:131721
|
|
premature death |
J:131721
|
Krastm4Tyj/Kras+
Tg(Fabp7-cre,-lacZ)3Gtm/0
involves: 129S4/SvJae * C57BL/6 * CBA
|
abnormal astrocyte morphology |
J:139866
|
|
abnormal brain development |
J:139866
|
|
abnormal CNS glial cell morphology |
J:139866
|
|
abnormal hippocampus morphology |
J:139866
|
|
normal
endocrine/exocrine gland phenotype |
J:138868
|
|
normal
growth/size/body region phenotype |
J:138868,
J:139866
|
|
normal
mortality/aging |
J:139866
|
|
normal
nervous system phenotype |
J:139866
|
Krastm4Tyj/Kras+
Tg(Cela1-cre/ERT)1Dam/0
involves: 129S4/SvJae
|
increased lung non-small cell carcinoma incidence |
J:197054
|
|
increased pancreas tumor incidence |
J:197054
|
Krastm4Tyj/Kras+
Tg(Gfap-cre)77.6Mvs/0
involves: 129 * BALB/c * C57BL/6NHsd
|
normal
neoplasm |
J:154673
|
Krastm4Tyj/Kras+
Tg(Cdh5-cre/ERT2)1Rha/0
involves: 129S4/SvJae * FVB
|
abnormal brain vasculature morphology |
J:312482
|
|
arteriovenous malformation |
J:312482
|
|
intracranial hemorrhage |
J:312482
|
|
postnatal lethality, incomplete penetrance |
J:312482
|
Krastm4Tyj/Kras+
Tg(IVL-cre/ERT2)1Blpn/0
involves: 129S4/SvJae * C57BL/6
|
epidermal hyperplasia |
J:172048
|
|
increased facial tumor incidence |
J:172048
|
|
increased lip tumor incidence |
J:172048
|
|
increased skin papilloma incidence |
J:172048
|
|
increased skin tumor incidence |
J:172048
|
|
thick epidermis |
J:172048
|
Krastm4Tyj/Kras+
Tg(Slco1c1-icre/ERT2)1Mrks/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 * FVB
|
abnormal brain vasculature morphology |
J:312482
|
|
arteriovenous malformation |
J:312482
|
|
intracranial hemorrhage |
J:312482
|
Krastm4Tyj/Kras+
Sftpctm1.1(cre/ERT2)Ptch/Sftpc+
involves: 129P2/OlaHsd * C57BL/6 * FVB
|
increased lung adenoma incidence |
J:195738
|
Krastm4Tyj/Kras+
Tg(Tg-cre/ERT2)#Mmcm/0
involves: 129S4/SvJae * FVB/NCr
|
normal
endocrine/exocrine gland phenotype |
J:172205
|
Krastm4Tyj/Krastm4Tyj
B6.129S4-Krastm4Tyj
|
increased cell proliferation |
J:187371
|
Krastm4Tyj/Krastm4Tyj
Bhlha15tm3(cre/ERT2)Skz/Bhlha15+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ
|
increased pancreatic intraepithelial neoplasia incidence |
J:142189
|
Krastm4Tyj/Krastm4Tyj
Ptf1atm1(cre)Hnak/Ptf1a+
involves: 129S4/SvJae
|
increased pancreatic intraepithelial neoplasia incidence |
J:162125
|
Krastm4Tyj/Krastm4Tyj
Tg(Cela1-cre/ERT2)1Stof/0
involves: 129S4/SvJae * C57BL/6 * SJL
|
increased pancreatic intraepithelial neoplasia incidence |
J:142189
|
Krastm4Tyj/Krastm4Tyj
Tg(Cela1-cre/ERT)1Dam/0
involves: 129S4/SvJae
|
increased pancreatic intraepithelial neoplasia incidence |
J:142188
|
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
increased pancreatic intraepithelial neoplasia incidence |
J:151781
|
|
pancreas cyst |
J:151781
|
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre/Esr1*)35.10Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA
|
increased pancreatic intraepithelial neoplasia incidence |
J:142188
|
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre/Esr1*)35.10Dam/0
involves: 129S4/SvJae * C57BL/6 * SJL
|
normal
neoplasm |
J:142189
|
Krastm5Tyj/Kras+
involves: 129S4/SvJae * C57BL/6
|
increased lung tumor incidence |
J:172206
|
Excel File
Analysis Tools